Abstract
Despite the widespread use of the COVID-19 vaccines, the search for effective antiviral drugs for the treatment of patients infected with SARS-CoV-2 is still relevant. Genetic variability leads to the continued circulation of new variants of concern (VOC). There is a significant decrease in the effectiveness of antibody-based therapy, which raises concerns about the development of new antiviral drugs with a high spectrum of activity against VOCs. We synthesized new analogs of uracil derivatives where uracil was substituted at the N 1 and N 3 positions. Antiviral activity was studied in Vero E6 cells against VOC, including currently widely circulating SARS-CoV-2 Omicron. All synthesized compounds of the panel showed a wide antiviral effect. In addition, we determined that these compounds inhibit the activity of recombinant SARS-CoV-2 RdRp. Our study suggests that these non-nucleoside uracil-based analogs may be of future use as a treatment for patients infected with circulating SARS-CoV-2 variants.
Keywords: COVID-19; RNA-dependent RNA polymerase; SARS-CoV-2; antiviral agents; non-nucleoside inhibitor.
【저자키워드】 COVID-19, SARS-CoV-2, Antiviral agents, RNA-dependent RNA polymerase, non-nucleoside inhibitor., 【초록키워드】 Treatment, Antiviral, VoC, variants of concern, omicron, antiviral drug, Antiviral effect, RNA, COVID-19 vaccines, VOCs, Patient, Effectiveness, circulation, Vero E6 cell, inhibitor, SARS-CoV-2 RdRp, Compound, Variability, significant decrease, circulating, uracil, derivative, circulating SARS-CoV-2 variants, widespread, effective, antibody-based therapy, raise, addition, inhibit, these compound, infected with SARS-CoV-2, 【제목키워드】 activity, concern, derivative,